COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Prospects Need A Boost To Lift Shares

With a price-to-sales (or "P/S") ratio of 0.5x COFCO Biotechnology Co., Ltd. (SZSE:000930) may be sending bullish signals at the moment, given that almost half of all the Chemicals companies in China have P/S ratios greater than 2.4x and even P/S higher than 5x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.

Check out our latest analysis for COFCO Biotechnology

How COFCO Biotechnology Has Been Performing

Recent times have been advantageous for COFCO Biotechnology as its revenues have been rising faster than most other companies. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the share price, and thus the P/S ratio. If the company manages to stay the course, then investors should be rewarded with a share price that matches its revenue figures.

Want the full picture on analyst estimates for the company? Then our free report on COFCO Biotechnology will help you uncover what's on the horizon.

How Is COFCO Biotechnology's Revenue Growth Trending?

There's an inherent assumption that a company should underperform the industry for P/S ratios like COFCO Biotechnology's to be considered reasonable.

If we review the last year of revenue growth, the company posted a worthy increase of 5.3%. Ultimately though, it couldn't turn around the poor performance of the prior period, with revenue shrinking 13% in total over the last three years. Accordingly, shareholders would have felt downbeat about the medium-term rates of revenue growth.

Turning to the outlook, the next year should bring diminished returns, with revenue decreasing 0.9% as estimated by the sole analyst watching the company. With the industry predicted to deliver 24% growth, that's a disappointing outcome.

With this in consideration, we find it intriguing that COFCO Biotechnology's P/S is closely matching its industry peers. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.

What Does COFCO Biotechnology's P/S Mean For Investors?

Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

With revenue forecasts that are inferior to the rest of the industry, it's no surprise that COFCO Biotechnology's P/S is on the lower end of the spectrum. As other companies in the industry are forecasting revenue growth, COFCO Biotechnology's poor outlook justifies its low P/S ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

Many other vital risk factors can be found on the company's balance sheet. Our free balance sheet analysis for COFCO Biotechnology with six simple checks will allow you to discover any risks that could be an issue.

If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.